Detalhe da pesquisa
1.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36737752
2.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35877084
3.
Current evidence between hospital volume and perioperative outcome: Prospective assessment of robotic radical prostatectomy safety profile in a regional center of medium annual caseload.
Can Urol Assoc J
; 15(3): E153-E159, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-32807280
4.
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer.
Commun Biol
; 4(1): 119, 2021 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33500545
5.
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Science
; 374(6564): 216-224, 2021 Oct 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34618582
6.
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).
Cancers (Basel)
; 11(8)2019 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31374981